Newer Oral Anticoagulants Should Be Used as First-Line Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation and Risk Factors for Stroke or Thromboembolism
- 1 January 2012
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation
- Vol. 125 (1) , 159-164
Abstract
The incidence of atrial fibrillation (AF) appears to be increasing, even after adjustment for aging of the population.1 One in 4 people is projected to develop AF in his or her lifetime.2 Patients with AF have a 5-fold increased risk of stroke, and it is estimated that 15% to 20% of all strokes are attributable to AF. Moreover, death and disability from stroke complicating AF are particularly high.3 Thus, stroke related to AF is a substantial and growing public health burden. Response by Ansell on p 164 Warfarin results in a two-thirds reduction in stroke on the basis of a meta-analysis of the randomized controlled trials4 (Figure). However, warfarin is grossly underused. In a relatively healthy insured population, ≈55% of eligible patients with AF received warfarin, and the rates dropped off substantially in the elderly, who have the greatest need.5 This low proportion of use and even greater underuse in higher-risk patients have been consistent findings across a number of US and European registries.6–8 In addition, not only is warfarin underused, but when it is used, it is used suboptimally.5 An inception cohort of elderly patients started on warfarin found that 28% of patients had discontinued warfarin by 1 year.9 Rates of major bleeding were very high, at >20% for patients with CHADS2 (an acronym for congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and prior stroke or transient ischemic attack) score ≥4, during the first year, illustrating the vulnerability of patients on warfarin during initiation. International normalized ratios (INRs) were in the target range of 2.0 to 3.0 only 58% of the time. Reasons for underuse of warfarin and inability to consistently achieve target INR, at least in part, relate to pharmacological properties of the drug, including …Keywords
This publication has 28 references indexed in Scilit:
- Heart Disease and Stroke Statistics—2011 UpdateCirculation, 2011
- Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic ReviewThe American Journal of Medicine, 2010
- Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial FibrillationCirculation: Cardiovascular Quality and Outcomes, 2008
- Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial FibrillationAnnals of Internal Medicine, 2007
- Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial FibrillationCirculation, 2007
- Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future PrevalenceCirculation, 2006
- Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial FibrillationEuropean Heart Journal, 2006
- Hospitalized Patients With Atrial Fibrillation and a High Risk of Stroke Are Not Being Provided With Adequate AnticoagulationJACC, 2005
- Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) StudyAnnals of Internal Medicine, 1999
- Stroke Severity in Atrial FibrillationStroke, 1996